Oritavancin activity against staphylococcus aureus causing invasive infections in u.s. and european hospitals: A 5-year international surveillance program

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 5, 2014, Pages 2921-2924

  Mendes, Rodrigo E ^a   Sader, Helio S ^a   Flamm, Robert K ^a   Farrell, David J ^a   Jones, Ronald N ^a  

^a JMI LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; DAPTOMYCIN; GENTAMICIN; LINEZOLID; ORITAVANCIN; RIFAMPICIN; VANCOMYCIN; ANTIINFECTIVE AGENT; GLYCOPEPTIDE;

ANTIBACTERIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE SURVEILLANCE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; EUROPE; HEALTH SURVEY; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; PHENOTYPE; PRIORITY JOURNAL; SINGLE DRUG DOSE; UNITED STATES; DRUG EFFECTS; HOSPITAL; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EUROPE; GLYCOPEPTIDES; HOSPITALS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS AUREUS; UNITED STATES;

EID: 84898655911     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02482-13     Document Type: Article

References (10)

1. Keynan Y, Rubinstein E. 2013. Staphylococcus aureus bacteremia, risk factors, complications, and management. Crit. Care Clin. 29:547-562. http://dx.doi.org/10.1016/j.ccc.2013.03.008.
2. Montassier E, Batard E, Gastinne T, Potel G, de La Cochetière MF. Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance. Eur. J. Clin. Microbiol. Infect. Dis. 32:841-850. http://dx.doi.org/10.1007/s10096-013-1819-7.
3. Joo J, Yamaki J, Lou M, Hshieh S, Chu T, Shriner KA, Wong-Beringer A. 2013. Early response assessment to guide management of methicillinresistant Staphylococcus aureus bloodstream infections with vancomycin therapy. Clin. Ther. 35:995-1004. http://dx.doi.org/10.1016/j.clinthera.2013.05.018.
4. van Hal SJ, Lodise TP, Paterson DL. 2012. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-Analysis. Clin. Infect. Dis. 54: 755-771. http://dx.doi.org/10.1093/cid/cir935.
5. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Rybak MJ, Talan DA, Chambers HF. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin. Infect. Dis. 52: 285-292. http://dx.doi.org/10.1093/ cid/cir034.
6. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically-9th ed. Approved standard M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Clinical and Laboratory Standards Institute. 2013. Performance standards for antimicrobial susceptibility testing; 23rd informational supplement. CLSI document M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Gould IM, Miró JM, Rybak MJ. 2013. Daptomycin: the role of high-dose and combination therapy for Gram-positive infections. Int. J. Antimicrob. Agents 42:202-210. http://dx.doi.org/10.1016/j.ijantimicag.2013.05. 005.
9. Zhanel GG, Schweizer F, Karlowsky JA. 2012. Oritavancin: mechanism of action. Clin. Infect. Dis. 54(Suppl 3):S214-S219. http://dx.doi.org/10.1093/cid/ cir920.
10. Arhin FF, Draghi DC, Pillar CM, Moeck G, Sahm DF. 2012. Correlation between oritavancin and vancomycin minimum inhibitory concentrations in staphylococci. Int. J. Antimicrob. Agents 40:562-563. http://dx.doi.org/10.1016/ j.ijantimicag.2012.06.019.